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Diﬀ erent liposomal 
amphotericin B 
formulations for 
visceral leishmaniasis
Author’s reply
Control of visceral leishmaniasis 
requires access to low-cost, safe, and 
effective treatment. Amphotericin 
causes infusion-related fever, rigor, 
and nephrotoxicity, limiting its use. 
Ambisome—a liposomal ampho tericin 
manufactured by Gilead—is better 
tolerated and is eﬀ ective as a single 
dose. However, its limited production 
is inadequate for all cases of visceral 
leishmaniasis, and its cost needs 
further reduction.1
The liposomal or lipid-associated 
amphotericin products Amphotec, 
Abelcet, and Ambisome have diﬀ erent 
lipids, shapes, sizes, toxic effects, 
pharmacokinetics, manufacturing 
processes, and formulations, yet 
similar efficacies. Ambisome and 
Anfogen (a liposomal amphotericin by 
Genpharma, Argentina, withdrawn for 
further development) have the same 
composition but are manufactured 
diﬀ erently and have diﬀ erent particle 
sizes, toxic eﬀ ects, and eﬃ  cacy in the 
aspergillosis mouse model.2
The liposomal amphotericin 
Fungi some, developed by academic 
institutions3 and marketed in India, is 
indeed not a generic of Ambisome: 
it contains different lipids (soy 
phosphadidyl choline and cholesterol), 
and has a different vesicle size, 
formulation, and pharmaco kinetics in 
preclinical and clinical phase 1 studies. 
It is safe and eﬀ ective in animal models 
of mouse aspergil losis and visceral 
leishmaniasis; in phases 2, 3, and 4 of 
systemic mycosis; in a phase 2 dose-
ﬁ nding study of visceral leishmaniasis;3 
and in a single-dose study in visceral 
leishmaniasis (personal communica-
tion, Lifecare). 
WHO prequalification is useful 
for UN organisations to increase 
access and aﬀ ordability, and includes 
products that comply with Good 
Manufacturing Practice, have been 
studied as per Good Clinical Practice, 
and that meet WHO standards.
But for liposomal amphotericin 
there are no WHO standards. The 
2002 draft of the US Food and Drug 
Administration guidance document 
is under revision. European Medicines 
Agency 2013 guidelines are based on 
innovator products as reference, the 
extent and complexity of non-clinical 
and clinical studies to be defined 
on a case-by-case basis.4 Indian 
pharmaco poeal standards have been 
withdrawn owing to inconsistencies 
with marketed products. Gaspani and 
Milani1 suggest that pharmaceutical 
characterisation and clinical pharma-
cokinetics are suﬃ  cient for a product 
to be designated the same as the 
innovator. For a product to be 
designated similar but not the same, 
preclinical animal pharmaco kinetic and 
eﬃ  cacy data are also needed. However, 
liposomal drug distribution is aﬀ ected 
by disease. Targeting, dose, and 
clinical eﬃ  cacy are diﬀ erent in visceral 
leishmaniasis and mycosis, thus 
necessitating specific preclinical and 
clinical studies for safety and eﬃ  cacy.
Despite preclinical and clinical 
studies on Fungisome,3 Thomas Dorlo 
and Manica Balasegaram conclude 
that Fungisome’s testing is inadequate 
and that it is diﬃ  cult to use. They miss 
the point of the need for economic 
alternatives to Ambisome, rational 
standards to ensure safety and 
eﬃ  cacy, post-marketing monitor ing, 
and concerted eﬀ orts by all to control 
this neglected disease.
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